YD Bio Limited Ordinary Shares (YDES)
StalwartFairStock Score: 41/100 — MIXED
Key Financials
| Current Price | $5.18 |
| Market Cap | $362M |
| P/E Ratio | -43.13 |
| ROE | -42.69% |
| Dividend Yield | —% |
| Sector | Healthcare |
Strengths
- Conservative balance sheet with debt-to-equity of just 0.00, providing financial flexibility
- Altman Z-Score of 288.1 confirms minimal bankruptcy risk and strong solvency
Concerns
- Weak Piotroski F-Score of 0/9 suggests deteriorating financial quality across multiple dimensions
AI Analysis
YD Bio Limited Ordinary Shares is a micro-cap healthcare company valued at $362 million. Revenue stands at $510,360. From a quality standpoint, YD shows weak Piotroski F-Score of 0/9 signaling deteriorating fundamentals and Altman Z-Score of 288.1 confirms fortress-level solvency. Our composite FairStock Score of 41/100 reflects below-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.
Bull Case
Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.
Bear Case
Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.
Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer